EX-10.26



 Exhibit 10.26 
 ARATANA THERAPEUTICS, INC. 
 AMENDMENT NO. 1 TO 

EMPLOYMENT AGREEMENT 
 THIS AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (this
“Amendment”) is made and entered into as of April 26, 2013, by and between ARATANA THERAPEUTICS, INC., a Delaware corporation (the
“Company”), and Steven St. Peter (the “Executive”). Capitalized terms used and not otherwise defined herein shall have the meanings given to them in the Original Agreement (as
defined below). 
 RECITALS 
 WHEREAS, the Company and the Executive are parties to that certain Employment Agreement, dated as of September 6, 2012 (the “Original
Agreement”); and 
 WHEREAS, in accordance with Section 10 of the Original Agreement,
the Company and the Executive desire to amend the Original Agreement as set forth in this Amendment. 
 NOW,
THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 AMENDMENT 
 1. AMENDMENTS TO ORIGINAL AGREEMENT. 
 1.1 Amendment to Section 2.2. The fourth sentence of Section 2.2 of the Original Agreement is hereby amended and restated in its entirety to read as follows: 

“Accordingly, the Executive agrees that during the Term and for (i) eighteen (18) months following the
termination of his employment by the Company without Cause (as defined below) or by the Executive for Good Reason (as defined below) during the Double-Trigger Period (as defined below), or (ii) twelve (12) months following the termination
of his employment for any other reason, the Executive shall not engage in competition with the Company and/or any of its Affiliates (as defined below), either directly or indirectly, in any manner or capacity, as adviser, principal, agent,
Affiliate, promoter, partner, officer, director, employee, stockholder, owner, co-owner, consultant or member of any association or otherwise, in any phase of the business of developing, licensing, manufacturing, distributing or marketing of
products or services that are in the same Field of Use (as defined below) or which are otherwise in competition with the actual or reasonably anticipated products or services of the Company at the time of his separation from the Company, except with
the prior written consent of the Board.” 







 1.2 Amendment to Section 3.2. Section 3.2 of the Original Agreement is
hereby amended and restated in its entirety to read as follows: 
 “3.2 Annual Bonus. The Executive
will be eligible to receive an annual cash bonus (the “Bonus”) of up to fifty percent (50%) of the Base Salary with respect to each calendar year, subject to the Executive’s continued employment with the Company as
of the end of such calendar year and contingent upon successful achievement of corporate objectives established from year to year by the Board (excluding the Executive). Any Bonus pursuant to this Section 3.2 shall be paid as promptly as
practicable following the end of the applicable calendar year, but not later than March 15th of the following calendar year.” 
 1.3 Amendment to Section 3.3.1. Section 3.3.1 of the Original Agreement is hereby retitled “Stock Options” and is hereby amended by adding the following subparagraphs
(iii) and (iv) following existing subparagraph (ii): 
 “(iii) On the date the Company’s
registration statement relating to its initial public offering becomes effective (the “IPO Effective Date”), the Company shall grant the Executive a stock option (the “IPO Stock Option”) pursuant to
the Company’s 2013 Incentive Award Plan or such other equity incentive plan or similar plan in effect on the IPO Effective Date (the “New Plan”) to purchase 250,000 shares of Common Stock (adjusted for any stock splits,
reverse stock splits or other changes affecting the shares of Common Stock that may occur prior to the date of grant), at a per share exercise price equal to the fair market value of a share of Common Stock on the date of grant. 

(iv) The IPO Stock Option shall be granted subject to the terms and conditions of the New Plan and a written option
agreement to be entered into by the Company and the Executive (the “IPO Option Agreement”). The IPO Option Agreement shall provide, among other things, that the shares of Common Stock underlying the IPO Stock Option (the
“IPO Option Shares”) shall vest: (x) as to 1/4th of the IPO Option Shares, upon the first (1st) anniversary of the date of grant of the IPO Stock Option; and (y) as to the remaining IPO Option Shares, in equal
monthly installments over the next thirty-six (36) months such that all shares shall be vested as of the fourth (4th) anniversary of the date of grant of the IPO Stock Option, subject to the Executive’s continued employment with the
Company on each such vesting date; provided, however, that: (a) the IPO Stock Option shall be subject to accelerated vesting as provided in Section 4.5.1 and Section 4.5.3(iii); and (b) “early exercise” of
the IPO Stock Option shall be permitted pursuant to the terms of the New Plan and the IPO Option Agreement.” 

  
 2 








 1.4 Amendment to Section 3.3.4. Section 3.3.4 of the Original Agreement is
hereby amended and restated in its entirety to read as follows: 
 3.3.4 Acceleration of Equity
Compensation. Immediately prior to the consummation of a Change in Control (as defined below), the vesting and exercisability of each of the Executive’s outstanding Existing Awards (as defined below) shall be automatically accelerated in
full.” 
 1.5 Amendment to Section 4.5.3. Section 4.5.3 of the Original Agreement is hereby amended and
restated in its entirety to read as follows: 
 “4.5.3 Without Cause or for Good Reason. If the
Company terminates the Executive’s employment without Cause or the Executive terminates his employment hereunder for Good Reason, the Company shall pay to the Executive the Base Salary and accrued and unused vacation benefits earned through the
date of termination at the rate in effect at the time of termination, plus all other amounts to which the Executive is entitled under any compensation plan or practice of the Company at the time of termination, less standard deductions and
withholdings. In addition, subject to the Executive’s: (i) furnishing to the Company an executed waiver and release of claims in substantially the form attached hereto as Exhibit B (which form may be amended to comply with legal
requirements arising after the Effective Date) (the “Release”) no later than forty-five (45) days following the Executive’s termination; and (ii) allowing the Release to become effective in accordance with its
terms, the Executive shall be entitled to the following: 
 (i) payment in an amount equal to 100% of the
Executive’s annual Base Salary in effect at the time of termination (or, in the event the termination occurs on account of or within twelve (12) months following the date of the consummation of a Change in Control (as defined below) (such
period, the “Double-Trigger Period”), an amount equal to 150% of the sum of (A) the Base Salary in effect at the time of termination, plus (B) the target cash bonus in effect for the year of termination) (with the
amount of the Base Salary determined prior to any reduction in the Base Salary that would give rise to the Executive’s right to voluntarily resign for Good Reason pursuant to Section 4.6.2), less standard deductions and withholdings, paid
in equal installments over a period of twelve (12) months (or eighteen (18) months, in the event the termination occurs during the Double-Trigger Period) pursuant to the Company’s standard payroll practices (the “Cash
Severance”); 
 (ii) should the Executive elect to continue Company-sponsored group health insurance
benefits in accordance with the provisions of COBRA or State Continuation, as applicable, following the date of termination, to the extent that doing so will not result in adverse tax consequences or violate applicable law, the Company shall pay the
full premium for such group health insurance continuation benefits for the Executive and any eligible dependents for a period of twelve (12) months (or eighteen (18) months, in the event the termination occurs during the


  
 3 








 
Double-Trigger Period) after the effective date of the Release; provided, however, that any such payments will cease if the Executive voluntarily enrolls in a health insurance plan
offered by another employer or entity during the period in which the Company is paying such premiums. The Executive agrees to promptly notify the Company in writing of any such enrollment. For purposes of this Section 4.5.3(ii), references to
COBRA or State Continuation premiums shall not include any amounts payable by the Executive under an Internal Revenue Code Section 125 health care reimbursement plan; and 

(iii) the vesting and/or exercisability of each of the Executive’s outstanding stock awards (including any stock
options, restricted stock, founder’s stock or other awards granted to the Executive by the Company) shall be automatically accelerated on the effective date of the Release as to the number of stock awards that would have vested over the twelve
(12) month period following the date of termination had the Executive remained continuously employed by the Company during such period; provided, however, that in the event that the termination occurs during the Double-Trigger
Period, the vesting and exercisability of each of the Executive’s outstanding New Awards (as defined below) shall be automatically accelerated in full, which shall mean at target for any portion of the New Awards that vests based on the
achievement of performance goals. 
 Notwithstanding the foregoing, in the event that the Company terminates the
Executive’s employment without Cause but after providing the Executive with: (i) written notice of the Board’s good-faith determination that the Executive’s participation in other activities pursuant to Section 2.1 is
interfering with the Executive’s performance of his duties under this Agreement; and (ii) a period of thirty (30) days to remedy such situation to the satisfaction of the Board in its reasonable discretion, the Executive shall be
entitled, subject to the provisions of this Section 4.5.3 (including, for the avoidance of doubt, the Executive’s (a) furnishing to the Company the Release no later than forty-five (45) days following the Executive’s
termination and (b) allowing such Release to become effective in accordance with its terms), to receive one-half of the benefits set forth in this Section 4.5.3.” 

1.6 Amendment to Section 4.6. Section 4.6 of the Original Agreement is hereby amended by adding the following
definitions: 
 “4.6.5 Existing Awards. “Existing Awards” shall mean the
Consulting Option, the Stock Option, the First Restricted Stock Award and the Second Restricted Stock Award. 

4.6.6 New Awards. “New Awards” shall mean the IPO Stock Option and any other stock options,
restricted stock or other equity awards granted to the Executive by the Company, with the exception of the Existing Awards. 

  
 4 








 2. MISCELLANEOUS 

2.1 Effective Date. This Amendment shall become effective on the IPO Effective Date, if and only if the following conditions (the
“Conditions”) are satisfied: (i) the Executive is still employed by the Company on the IPO Effective Date, and (ii) the IPO Effective Date is no later than September 30, 2013. For the avoidance of doubt, if
either of the Conditions is not satisfied, this Amendment shall be of no force or effect and shall not become effective. 

2.2 No Other Amendment. Except as specifically amended by this Amendment, the terms and conditions of the Original Agreement shall
remain unchanged and in full force and effect. 
 2.3 Counterparts; Execution by Facsimile. This Amendment may be
executed in any number of counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. The exchange of copies of this Amendment and of signature pages thereto by facsimile
transmission or by e-mail transmission in portable digital format, or similar format, shall constitute effective execution and delivery of such instrument(s) by the parties and may be used in lieu of the original Amendment for all purposes.

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 5 








 IN WITNESS WHEREOF, the
parties have duly executed and delivered this AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT as of the date first written above. 

 

			
	COMPANY:
	
	ARATANA THERAPEUTICS, INC.
		
	By:	 	/s/ Jay Lichter
	Name:	 	Jay Lichter
	Its:	 	Chairman
		
	Dated:	 	4/26/2013

  

			
	EXECUTIVE:
	
	/s/ Steven St. Peter
	STEVEN ST. PETER
		
	Dated:	 	4/26/2013

 [SIGNATURE PAGE TO AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT]